UTHR – United Therapeutics Corporation
UTHR — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
6.72
Margin Of Safety %
6
Put/Call OI Ratio
0.6
EPS Next Q Diff
6.15
EPS Last/This Y
-2.12
EPS This/Next Y
4.13
Price
523.04
Target Price
600.64
Analyst Recom
1.56
Performance Q
1.59
Upside
17.4%
Beta
0.8
Ticker: UTHR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | UTHR | 504.1 | 0.74 | 1.15 | 27243 |
| 2026-03-02 | UTHR | 513.86 | 0.66 | 0.72 | 25653 |
| 2026-03-03 | UTHR | 498.09 | 0.66 | 0.31 | 33033 |
| 2026-03-04 | UTHR | 490.45 | 0.66 | 13.04 | 33138 |
| 2026-03-05 | UTHR | 484.58 | 0.68 | 1.33 | 33657 |
| 2026-03-06 | UTHR | 477.85 | 0.69 | 1.18 | 34232 |
| 2026-03-09 | UTHR | 529.62 | 0.70 | 0.36 | 35373 |
| 2026-03-10 | UTHR | 536.17 | 0.68 | 0.30 | 39010 |
| 2026-03-11 | UTHR | 544.85 | 0.64 | 0.54 | 43440 |
| 2026-03-12 | UTHR | 532.83 | 0.64 | 16.13 | 43816 |
| 2026-03-13 | UTHR | 532.82 | 0.64 | 16.13 | 43816 |
| 2026-03-17 | UTHR | 540.41 | 0.58 | 1.47 | 42900 |
| 2026-03-18 | UTHR | 530.83 | 0.59 | 2.08 | 43689 |
| 2026-03-19 | UTHR | 527.47 | 0.60 | 1.36 | 44138 |
| 2026-03-20 | UTHR | 524.85 | 0.61 | 1.85 | 44746 |
| 2026-03-23 | UTHR | 520.86 | 0.56 | 1.03 | 40656 |
| 2026-03-24 | UTHR | 531.92 | 0.56 | 2.11 | 40941 |
| 2026-03-25 | UTHR | 542.1 | 0.57 | 1.18 | 41005 |
| 2026-03-26 | UTHR | 532.96 | 0.60 | 0.59 | 42512 |
| 2026-03-27 | UTHR | 522.95 | 0.60 | 0.53 | 42797 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | UTHR | 503.27 | 5.6 | 330.4 | 28.35 |
| 2026-03-02 | UTHR | 513.95 | 5.6 | 97.0 | 28.35 |
| 2026-03-03 | UTHR | 498.58 | 4.2 | -4.0 | 28.17 |
| 2026-03-04 | UTHR | 490.33 | 3.9 | -20.0 | 28.19 |
| 2026-03-05 | UTHR | 484.78 | 3.9 | -9.0 | 28.19 |
| 2026-03-06 | UTHR | 477.98 | 3.9 | -15.1 | 28.19 |
| 2026-03-09 | UTHR | 529.37 | 3.9 | 234.7 | 28.19 |
| 2026-03-10 | UTHR | 535.92 | 3.9 | 37.8 | 28.19 |
| 2026-03-11 | UTHR | 544.95 | 3.9 | 46.6 | 28.19 |
| 2026-03-12 | UTHR | 533.09 | 3.9 | -29.3 | 28.19 |
| 2026-03-13 | UTHR | 536.22 | 3.9 | 26.5 | 28.19 |
| 2026-03-17 | UTHR | 540.19 | 3.9 | 35.9 | 28.19 |
| 2026-03-18 | UTHR | 530.93 | 3.9 | -20.3 | 28.19 |
| 2026-03-19 | UTHR | 527.53 | 3.9 | 223.1 | 28.19 |
| 2026-03-20 | UTHR | 524.28 | 3.9 | 209.2 | 28.19 |
| 2026-03-23 | UTHR | 520.97 | 3.9 | 194.9 | 28.19 |
| 2026-03-24 | UTHR | 532.25 | 3.9 | 243.3 | 28.19 |
| 2026-03-25 | UTHR | 541.81 | 3.9 | 284.3 | 28.19 |
| 2026-03-26 | UTHR | 532.66 | 3.9 | 245.1 | 28.01 |
| 2026-03-27 | UTHR | 523.04 | 3.9 | 203.8 | 28.01 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | UTHR | -43.90 | -3.88 | 4.43 |
| 2026-03-02 | UTHR | -43.47 | -0.64 | 4.35 |
| 2026-03-03 | UTHR | -43.40 | -0.64 | 4.35 |
| 2026-03-04 | UTHR | -43.61 | -0.64 | 4.35 |
| 2026-03-05 | UTHR | -43.62 | -0.64 | 4.35 |
| 2026-03-06 | UTHR | -43.62 | -0.64 | 4.35 |
| 2026-03-09 | UTHR | -43.83 | -0.40 | 4.35 |
| 2026-03-10 | UTHR | -43.60 | -0.40 | 4.35 |
| 2026-03-11 | UTHR | -43.80 | -0.40 | 4.09 |
| 2026-03-12 | UTHR | -43.84 | -0.40 | 4.09 |
| 2026-03-13 | UTHR | -43.84 | -0.40 | 4.09 |
| 2026-03-17 | UTHR | -43.71 | -0.39 | 4.09 |
| 2026-03-18 | UTHR | -43.51 | -0.39 | 4.09 |
| 2026-03-19 | UTHR | -43.89 | -0.39 | 4.09 |
| 2026-03-20 | UTHR | -43.85 | -0.39 | 4.09 |
| 2026-03-23 | UTHR | -44.08 | -0.37 | 4.09 |
| 2026-03-24 | UTHR | -44.02 | -0.37 | 4.09 |
| 2026-03-25 | UTHR | -44.03 | -0.37 | 6.72 |
| 2026-03-26 | UTHR | -44.27 | -0.37 | 6.72 |
| 2026-03-27 | UTHR | -44.68 | -0.37 | 6.72 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.78
Avg. EPS Est. Current Quarter
6.73
Avg. EPS Est. Next Quarter
6.93
Insider Transactions
-44.68
Institutional Transactions
-0.37
Beta
0.8
Average Sales Estimate Current Quarter
804
Average Sales Estimate Next Quarter
826
Fair Value
554.92
Quality Score
100
Growth Score
98
Sentiment Score
45
Actual DrawDown %
4.8
Max Drawdown 5-Year %
-33
Target Price
600.64
P/E
18.74
Forward P/E
15.87
PEG
1.37
P/S
7.2
P/B
3.22
P/Free Cash Flow
22.02
EPS
27.9
Average EPS Est. Cur. Y
28.01
EPS Next Y. (Est.)
32.13
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
41.94
Relative Volume
0.76
Return on Equity vs Sector %
-8.5
Return on Equity vs Industry %
11.7
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.59
EBIT Estimation
203.8
◆
UTHR
Healthcare
$522.83
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
52.6
Range 1M
68.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
4.9%
EPS NY
12.7%
52W%
91.2%
Long-Term Value
Quality companies, undervalued
WATCH
🟡 HOLD
+22.4% upside
Upside
+22.4%
Quality
100
MoS
6%
United Therapeutics CorporationSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1400
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
UTHR
Latest News
—
Caricamento notizie per UTHR…
stock quote shares UTHR – United Therapeutics Corporation Stock Price stock today
news today UTHR – United Therapeutics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch UTHR – United Therapeutics Corporation yahoo finance google finance
stock history UTHR – United Therapeutics Corporation invest stock market
stock prices UTHR premarket after hours
ticker UTHR fair value insiders trading